ArticleRSC advances2019
Novel biodegradable and non-fouling systems for controlled-release based on poly(ε-caprolactone)/Quercetin blends and biomimetic bacterial S-layer coatings.
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recent Developments in Lactone Monomers and Polymer Synthesis and Application.Materials (Basel, Switzerland) · 2021Review
- Crystallization Behavior and Mechanical Properties of Poly(ε-caprolactone) Reinforced with Barium Sulfate Submicron Particles.Materials (Basel, Switzerland) · 2021Article
- Application of quercetin flavonoid based hybrid nanocomposites: A review.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
- Preparation of quercetin-nicotinamide cocrystals and their evaluation underRSC advances · 2020Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is a strong antioxidant with low bioavailability due to its high crystallinity. A further drawback is that Quercetin has potentially toxic effects at high concentrations. To improve this low water solubility, as well as control the concentration of the flavonoid in the body, Quercetin is incorporated into a polymeric matrix to form an amorphous solid dispersion (ASD) stable enough to resist the recrystallization of the drug. For this purpose, miscible poly(ε-caprolactone) (PCL) and Quercetin (Q) blends are prepared, provided that they have complementary interacting groups. For compositions in which the flavonoid remains in an amorphous state thanks to the interactions with polymer chains, various PCL/Q drug release platforms are fabricated: micrometric films by solvent casting, nanometric films by spin coating, and nanofibers by electrospinning. Then, the potential use of bacterial S-layer proteins as release-preventive membranes is tested on PCL-Quercetin blends, due to their ability to construct a biomimetic coating including nanometric pores. For all the platforms, the SbpA coating can maintain a stable release under the toxicity level of Quercetin. Accordingly, a PCL/Q system with an S-layer coating allows the design of versatile bioavailable Quercetin eluting devices that prevent toxicity and biofouling issues.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.